PT-141 (Bremelanotide) Future Formulations & Pipeline
HealthRX.com
Vyleesi is the only approved bremelanotide; no oral form exists
Key numbers
- 1.75 mgApproved single as-needed dose strength of Vyleesi, the only approved form, for premenopausal women with acquired HSDDSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 45 minutesMinimum time before anticipated sexual activity to use an as-needed Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Women on Vyleesi reporting nausea in pooled phase 3 trials, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximal systolic blood pressure increase after a dose (diastolic increase was 3 mmHg)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
From the public record
Registered clinical studies of bremelanotide
ClinicalTrials.gov lists 10 registered studies that name bremelanotide as an intervention as of 2026-11-11. Of these, 0 are recruiting, 9 are completed and 3 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 10 |
| Recruiting now | 0 |
| Not yet recruiting | 0 |
| Completed | 9 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 (including phase 2/3) | 3 |
| Phase 2 (including phase 1/2) | 4 |
| Phase 1 | 1 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches bremelanotide, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
From the public record
Published papers mentioning bremelanotide
PubMed indexes 96 papers that mention bremelanotide in the title or abstract, 76 of them published from 2016 to 2025. The count for 2025 is 12 and for 2024 is 8.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 96 | |
| Published 2016 to 2025 | 76 | |
| Published in 2025 | 12 | |
| Published in 2024 | 8 | |
| Busiest year since 2016 | 2022 | 14 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'bremelanotide' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
From the public record
Patents and generic approvals for bremelanotide
The FDA Orange Book lists 0 approved generic applications for bremelanotide across 1 listed product. 4 listed patents have not yet expired, the last on 2041-04-29.
| Measure | Value |
|---|---|
| Brand-name applications (NDA) | 1 |
| Approved generic applications (ANDA) | 0 |
| Listed patents not yet expired | 4 |
| Latest listed patent expiry | 2041-04-29 |
| Earliest approval date on file | 2019-06-21 |
| Products not marked discontinued | 1 of 1 |
How this was calculated
Selected Orange Book products whose only active ingredient is this substance, then counted applications by type and the distinct patents and exclusivities listed against them. Expired patents are left out.
All single-ingredient bremelanotide products in the Orange Book, every brand and strength, files dated 2026-10-09
An approved generic or an expired patent does not show that a generic is on sale. Launch timing also depends on litigation, settlements and supply. Biologics and compounded products are not in the Orange Book.
At a glance
- Approved form / 1.75 mg subcutaneous autoinjector (Vyleesi) [1]
- Approval / June 21, 2019, NDA 210557 [2]
- Approved use / Acquired, generalized HSDD in premenopausal women [1]
- Other route in human data / Intranasal, in small early studies [3][4]
- Oral or depot product / None approved [1]
- Peak and half-life / Median Tmax about 1 hour; mean terminal half-life about 2.7 hours [1]
What is approved right now
Vyleesi is the FDA-approved bremelanotide product: 1.75 mg subcutaneously in a prefilled autoinjector, prescription only, NDA 210557, approved June 21, 2019, now held by Cosette Pharmaceuticals [1][2]. It is indicated for premenopausal women with acquired, generalized HSDD — low sexual desire causing marked distress or interpersonal difficulty not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug — and the label states it is not indicated for postmenopausal women, for men, or to enhance sexual performance [1].
The approved regimen is 1.75 mg subcutaneously in the abdomen or thigh, used as needed at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and more than 8 doses per month not recommended [1]. The label describes only this autoinjector; no oral or depot bremelanotide product is approved [1]. Products sold as compounded or research-use 'PT-141' are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][5].
Questions worth asking
What the early intranasal studies found
The human data on a non-injection route come from small intranasal studies. In 2004, Diamond and colleagues gave intranasal PT-141 to healthy men and to men with mild-to-moderate erectile dysfunction; erectile response was significantly greater than placebo at doses above 7 mg, and flushing and nausea were the most common adverse events [4]. In 2006, a single 20 mg intranasal dose was given to 18 premenopausal women with female sexual arousal disorder in a double-blind crossover study, and more women reported moderate or high sexual desire than after placebo (P=0.0114) [3]. The label's alcohol interaction study, a clinical pharmacology study, also used a 20 mg intranasal dose, about 2.5-fold the Cmax of the approved 1.75 mg subcutaneous dose [1].
Safety profile of the approved injection
In the pooled phase 3 trials (1,247 women), nausea was reported by 40.0% on Vyleesi vs 1.3% on placebo, flushing 20.3% vs 0.3%, injection site reactions 13.2% vs 8.4% and headache 11.3% vs 1.9%; 13% used anti-nausea medicine, and discontinuation because of adverse reactions was 18% vs 2% [1]. In a single-dose study of 228 healthy women, pre-treatment with 8 mg oral ondansetron did not reduce nausea, and the label does not recommend it [1]. Maximal blood pressure increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose, with a heart rate reduction of up to 5 beats per minute [1].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is an oral form of PT-141 available?
What did the early intranasal bremelanotide studies find?
Is compounded or research PT-141 the same as Vyleesi?
Is a long-acting or depot bremelanotide approved?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
When to inject PT-141?
Vyleesi is used as needed: a 1.75 mg subcutaneous injection in the abdomen or thigh, given at least 45 minutes before anticipated sexual activity. No more than one dose is allowed in 24 hours, and more than 8 doses per month is not recommended.
What is bremelanotide nasal spray?
No bremelanotide nasal spray is approved. An intranasal form was tested in small early studies, including a 2004 study in men where doses above 7 mg produced a significantly greater erectile response than placebo, but that route was never approved. The only approved product is the 1.75 mg subcutaneous autoinjector, Vyleesi.
References
Show all 6 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004;16(1):51-9.
- Official web page.
- Clayton AH, Kingsberg SA, Goldstein I. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sex Med. 2018;6(2):59-74.